# KLOW peptide research: what the single-component studies measured | KLOW Online > KLOW peptide research is single-component research. KPV colitis, GHK-Cu matrix, BPC-157 tendon and gut, thymosin beta-4 wounds — cited findings. No study has tested the blend. There is no KLOW study. There are four single-peptide literatures. Here is what each one measured, and where it stops. ## The short version All **KLOW peptide research** is really four separate stories. No one has studied the blend. So this page reads the four peptides one at a time, with every number tied to a study. KPV calmed gut inflammation in mice and in human gut cells [2]. GHK-Cu (the copper peptide) pushed skin cells to make more collagen and shifted how a large share of their genes behaved [7][8]. BPC-157 healed transected tendons and stomach ulcers in rats and grew new blood vessels [5][4][3]. Thymosin beta-4 — the full protein behind the TB-500 fragment — closed wounds faster in rats [6]. Two cautions run through all of it. Most data come from cells and rodents, not people. And the four were never combined in any study — so every "they work together" claim is a guess, not a finding [1]. ## KPV: anti-inflammatory signaling and PepT1 uptake Nanomolar KPV is transported into intestinal epithelial cells via PepT1 (a transporter that pulls small peptides into the cells lining the gut), where it inhibits NF-kB and MAP-kinase inflammatory signaling and cuts pro-inflammatory cytokine secretion; oral KPV at 100 uM in drinking water reduced the severity of DSS- and TNBS-induced colitis in mice [2]. A second model agrees: KPV-treated mice in the DSS colitis model recovered earlier and regained body weight more strongly, with reduced colonic inflammatory infiltrate and myeloperoxidase activity. The effect was retained in MC1R-deficient mice — meaning it does not depend on the MC1 melanocortin receptor [14], and likely acts through inhibition of IL-1beta function rather than a classical melanocortin route [13]. The related tripeptide KdPT, a KPV analog, similarly protected the gut and preserved barrier function in colitis [15]. This is the gut-mucosa arm of the blend, established only at the single-peptide level. ## GHK-Cu: matrix synthesis and broad gene-expression modulation GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin; plasma GHK declines from about 200 ng/mL at age 20 to about 80 ng/mL by age 60; and topical GHK-Cu increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid [7]. At the gene level, GHK modulates expression of roughly 31.2% of human genes at a 50%-or-greater change threshold — raising 59% of affected genes and suppressing 41% — with strong stimulation of the protein-quality-control machinery and of DNA-repair and antioxidant gene sets [8]. The often-quoted "~4,000 genes" figure is an extrapolation; the >=50% threshold table reports on the order of 2,100 genes. GHK-Cu is the mass-dominant component of the canonical vial and the matrix arm of the blend. Its robust human data are topical and cosmetic, not systemic. ## BPC-157: tissue repair, gut cytoprotection and angiogenesis BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, and stimulated tendocyte outgrowth in vitro; doses of 10 microg, 10 ng or 10 pg per rat were given intraperitoneally once daily [5]. In the gastric-ulcer model, BPC-157 at 400 and 800 ng/kg inhibited ulcer formation by 45.7-65.6% and accelerated glandular-epithelium rebuilding, with intramuscular delivery outperforming intragastric [4]. Mechanistically, BPC-157 is pro-angiogenic via VEGFR2: it up-regulates VEGFR2 expression and drives the downstream VEGFR2-Akt-eNOS pathway, raising vessel density and accelerating blood-flow recovery in ischemic muscle [3]. A first formal pharmacokinetic study found linear kinetics, a very short elimination half-life and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism [9]. Recent work extends the picture: a 2025 rat study found BPC-157 reduced distant-organ damage in acute pancreatitis [16], and a 2025 literature-and-patent review catalogued its multifunctional preclinical activity while stressing that applications remain investigational [17]. A first-in-human IV safety pilot gave BPC-157 up to 20 mg to two healthy adults with no observed adverse events — a tiny sample, not an efficacy trial [18]. ## TB-500 and thymosin beta-4: wound closure and the fragment-versus-protein distinction In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, increased wound contraction by at least 11% by day 7, and raised collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration 2-3-fold [6]. The distinction the literature requires: TB-500 is the short N-acetylated heptapeptide Ac-LKKTET-Q, the actin-binding motif of the 43-amino-acid native protein thymosin beta-4. Most foundational efficacy data — and the human safety record, including a Phase 1 study of intravenous synthetic thymosin beta-4 in 40 healthy volunteers that was well tolerated to 1260 mg [11] — are for the full-length protein, not the short fragment. Marketing routinely conflates the two; the data do not automatically transfer. ## The blend itself: an absence on the record No controlled in-vivo or human study has ever tested the four-peptide KLOW blend — against monotherapy, against any subset, or against placebo [1]. Every synergy claim on this page and elsewhere is a mechanistic extrapolation from the single-component literature above. A 2026 Sports Medicine review of approved and unapproved peptide therapies — listing both TB-500/thymosin beta-4 and BPC-157 — concludes that many unapproved peptides show favorable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce, the potential for serious harm is real, and such compounds operate largely outside regulatory oversight [10]. Two 2024-2025 studies do place two of the arms in the same gut-mucosa space — a PepT1-targeted nanodrug co-assembling KPV with an immunosuppressant improved colitis in mice beyond either agent alone [19], and GHK-Cu reduced colonic inflammation in DSS colitis by suppressing inflammatory cytokines and restoring tight-junction proteins [20]. Both are single-agent or two-agent studies. Neither is the KLOW blend. --- Four peptides set down as four separate marks, each read against its own studies — with the missing combination data left as the one honest blank, and nothing here clinical, prescribed, or for sale.